Cytologic features of undifferentiated and dedifferentiated carcinomas of the endometrium.


Journal

Cancer cytopathology
ISSN: 1934-6638
Titre abrégé: Cancer Cytopathol
Pays: United States
ID NLM: 101499453

Informations de publication

Date de publication:
02 2021
Historique:
received: 27 07 2020
revised: 18 08 2020
accepted: 18 08 2020
pubmed: 17 9 2020
medline: 27 7 2021
entrez: 16 9 2020
Statut: ppublish

Résumé

Undifferentiated carcinoma (UC) is a rare, aggressive subtype of endometrial carcinoma. Dedifferentiated carcinomas (DCs) are UCs associated with a component of well differentiated endometrioid carcinoma. The authors sought to describe the morphologic features of UCs and DCs in cytologic specimens. Cytologic specimens from 23 women (aged 46-86 years; median age, 59 years) were reviewed, including cervicovaginal specimens (n = 7), peritoneal washings (n = 5), touch preparations of core biopsies from various sites (n = 5), fine-needle biopsies of lymph nodes (n = 3), ascitic fluid (n = 1), pleural fluid (n = 1), and intrauterine fluid (n = 1). There were 10 UCs (43%) and 13 DCs (57%). Tumor cells were arranged as single cells (9 UCs, 90%; 12 DCs, 92%) and 3-dimensional groups (8 UCs, 80%; 11 DCs, 85%). Most cases showed high nuclear-to-cytoplasmic ratios. Nuclear molding was observed in 3 UCs (30%) and in 5 DCs (38%). Nuclear chromatin was often coarsely granular 6 UCs, 60%; 9 DCs, 69%). Nucleoli were inconspicuous in some cases (6 UCs, 60%; 8 DCs, 62%) but were appreciable in others. Necrosis was observed in 5 UCs (50%) and in 5 DCs (38%). Most cases exhibited clean backgrounds, and a few showed acute inflammation. Comparison of the cytologic features of UCs and DCs did not reveal any statistically significant differences. UCs and DCs have a spectrum of cytomorphologic appearances that are not pathognomonic, but the presence of some of these (relatively uniform population of predominantly singly dispersed cells with high nuclear-to-cytoplasmic ratios and variably conspicuous nucleoli) should prompt consideration of UC and DC in the differential diagnosis.

Sections du résumé

BACKGROUND
Undifferentiated carcinoma (UC) is a rare, aggressive subtype of endometrial carcinoma. Dedifferentiated carcinomas (DCs) are UCs associated with a component of well differentiated endometrioid carcinoma. The authors sought to describe the morphologic features of UCs and DCs in cytologic specimens.
METHODS
Cytologic specimens from 23 women (aged 46-86 years; median age, 59 years) were reviewed, including cervicovaginal specimens (n = 7), peritoneal washings (n = 5), touch preparations of core biopsies from various sites (n = 5), fine-needle biopsies of lymph nodes (n = 3), ascitic fluid (n = 1), pleural fluid (n = 1), and intrauterine fluid (n = 1).
RESULTS
There were 10 UCs (43%) and 13 DCs (57%). Tumor cells were arranged as single cells (9 UCs, 90%; 12 DCs, 92%) and 3-dimensional groups (8 UCs, 80%; 11 DCs, 85%). Most cases showed high nuclear-to-cytoplasmic ratios. Nuclear molding was observed in 3 UCs (30%) and in 5 DCs (38%). Nuclear chromatin was often coarsely granular 6 UCs, 60%; 9 DCs, 69%). Nucleoli were inconspicuous in some cases (6 UCs, 60%; 8 DCs, 62%) but were appreciable in others. Necrosis was observed in 5 UCs (50%) and in 5 DCs (38%). Most cases exhibited clean backgrounds, and a few showed acute inflammation. Comparison of the cytologic features of UCs and DCs did not reveal any statistically significant differences.
CONCLUSIONS
UCs and DCs have a spectrum of cytomorphologic appearances that are not pathognomonic, but the presence of some of these (relatively uniform population of predominantly singly dispersed cells with high nuclear-to-cytoplasmic ratios and variably conspicuous nucleoli) should prompt consideration of UC and DC in the differential diagnosis.

Identifiants

pubmed: 32937020
doi: 10.1002/cncy.22351
pmc: PMC7854522
mid: NIHMS1624004
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

121-131

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States

Informations de copyright

© 2020 American Cancer Society.

Références

Int J Gynecol Pathol. 2006 Jan;25(1):52-8
pubmed: 16306785
Pathology. 2007 Feb;39(1):134-8
pubmed: 17365829
Mod Pathol. 2016 Mar;29(3):302-14
pubmed: 26743474
Appl Immunohistochem Mol Morphol. 2016 Sep;24(8):562-8
pubmed: 26371430
Pathology. 2015 Aug;47(5):439-45
pubmed: 26126041
Int J Gynecol Pathol. 2016 Sep;35(5):410-8
pubmed: 26598976
Diagn Cytopathol. 2015 Sep;43(9):756-62
pubmed: 26174064
Am J Surg Pathol. 2015 May;39(5):722-4
pubmed: 25871469
Mod Pathol. 2016 Dec;29(12):1586-1593
pubmed: 27562491
Hum Pathol. 2015 Oct;46(10):1514-20
pubmed: 26239622
Cancer Cell. 2017 Mar 13;31(3):411-423
pubmed: 28292439
Tokai J Exp Clin Med. 2015 Jun 20;40(2):29-35
pubmed: 26150180
Am J Surg Pathol. 2016 May;40(5):577-86
pubmed: 26945341
Am J Clin Pathol. 2007 Mar;127(3):385-97
pubmed: 17276948
Mod Pathol. 2017 Apr;30(4):539-548
pubmed: 28084340
Semin Diagn Pathol. 2016 Jul;33(4):198-203
pubmed: 27199077
Zhonghua Bing Li Xue Za Zhi. 2019 Aug 8;48(8):590-595
pubmed: 31422588
Mod Pathol. 2010 Jun;23(6):781-9
pubmed: 20305618
Int J Gynecol Cancer. 2019 Sep;29(7):1126-1133
pubmed: 31422353
Pathol Oncol Res. 2012 Apr;18(2):523-8
pubmed: 21448784
Diagn Cytopathol. 1997 Nov;17(5):333-8
pubmed: 9360045
Mod Pathol. 2016 Dec;29(12):1594
pubmed: 27895324
Pathol Oncol Res. 2020 Jul;26(3):1411-1416
pubmed: 31811476
Diagn Cytopathol. 2019 Dec;47(12):1297-1301
pubmed: 31386298
Diagn Cytopathol. 1999 Oct;21(4):284-6
pubmed: 10495324
Int J Gynecol Pathol. 2019 Jan;38 Suppl 1:S25-S39
pubmed: 30550482
Diagn Cytopathol. 2019 Jun;47(6):547-552
pubmed: 30706679
Arch Pathol Lab Med. 2013 Mar;137(3):438-42
pubmed: 23451754
Mod Pathol. 2018 Sep;31(9):1442-1456
pubmed: 29700418
Int J Clin Exp Pathol. 2014 Dec 01;7(12):8869-74
pubmed: 25674257
Semin Diagn Pathol. 2010 Nov;27(4):274-86
pubmed: 21309261
Int J Gynecol Pathol. 2010 Jul;29(4):343-50
pubmed: 20567148
Am J Surg Pathol. 2005 Oct;29(10):1316-21
pubmed: 16160474
Am J Clin Pathol. 2007 Aug;128(2):265-71
pubmed: 17638661
Int J Gynecol Pathol. 2019 Jan;38 Suppl 1:S40-S63
pubmed: 30550483
Histopathology. 2016 Nov;69(5):894-897
pubmed: 27334502
Mod Pathol. 2019 Nov;32(11):1675-1687
pubmed: 31190001
Proc Natl Acad Sci U S A. 2012 Jan 17;109(3):929-34
pubmed: 22223660
Korean J Pathol. 2014 Aug;48(4):327-30
pubmed: 25214869
Mod Pathol. 2016 Jan;29 Suppl 1:S92-103
pubmed: 26715176
Acta Cytol. 2002 May-Jun;46(3):465-9
pubmed: 12040638
Acta Cytol. 2002 Jul-Aug;46(4):790-2
pubmed: 12146057
Int J Gynecol Pathol. 2009 Mar;28(2):142-7
pubmed: 19188820
Am J Surg Pathol. 1992 Oct;16(10):926-38
pubmed: 1384368

Auteurs

Amir-Hossein Akbari (AH)

Department of Pathology, University Health Network, Toronto, Ontario, Canada.

Lu Wang (L)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.

Robert A Soslow (RA)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.

Rajmohan Murali (R)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH